Society for Endocrinology - a world-leading authority on hormones

EMA recommends approval of new somatostatin analogue pasireotide (Signifor) for Cushing’s disease (Reuters, 20 January 2012)

20 Jan 2012


The European Medicines Agency has made a positive recommendation to the European Commission for EU approval for Novartis' Signifor (pasireotide) in the treatment of Cushing's disease.

Full article